Recent moves in the industry include C-suite shuffle at Perspective Therapeutics and Bausch Health, plus Oculis Holding gets a new CDO and Tiziana Life Sciences gets a new CEO.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Vyepti revenues rise by nearly 70% in the first quarter.
As CEO Anderson backs high prices for innovative drugs in Europe
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.
Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
